XM does not provide services to residents of the United States of America.

Gossamer Bio gains after rival Aerovate scraps late-stage trial of lead drug



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>BUZZ-Gossamer Bio gains after rival Aerovate scraps late-stage trial of lead drug</title></head><body>

** Shares of drug developer Gossamer Bio GOSS.O rise 14% to 59 cents after competitor Aerovate Therapeutics AVTE.O scraps late-stage trial of lead lung disease drug

** Aerovate's sole product, called AV-101, failed on key goals in the mid-stage portion of a mid-to-late-stage study, sending shares down more than 92% to $1.89

** AV-101 was tested in adults with a pulmonary arterial hypertension (PAH), characterized by high blood pressure in the arteries of the lungs

** Gossamer's experimental therapy, seralutinib, is currently in late-stage development for PAH treatment

** Brokerage Leerink Partners said Aerovate's update has no efficacy readthrough to GOSS that has already generated encouraging mid-stage results

** "With AVTE's program now discontinued, there could be more PAH patients available for GOSS to potentially enroll" - brokerage

** Current treatment options include Merck's MRK.N Winrevair, which was approved by the U.S. FDA in March

** Including session's rise, GOSS down more than 34%



Reporting by Pratik Jain in Bengaluru

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.